William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update

April 17, 2024 By The ASCO Post Staff

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, details the fundamental shift in how clinicians now treat patients with endocrine-sensitive breast cancer, both advanced and early stage, by pairing antihormonal therapy with targeted treatment.

Related Content